CytRx Will Need 'Stunning' OS Data To Get Chemotherapy Agent Back On Track
CytRx Corp. saw is stock drop as low as $0.75 per share this week on the back of poor Phase III data for its lead drug – modified chemotherapy agent aldoxorubicin – which have left analysts questioning whether the company's plan for further examination can save this study.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.